This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Debulking Effect of Curretage on Basal Cell Carcinomas - a Histological Assessment.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00237107
First received: October 10, 2005
Last updated: July 18, 2016
Last verified: July 2016
  Purpose
The aim of this study was to compare histologically observed tumour infitration of basal cell carcinoma (bcc) lesions before and after curretage.A significant reduction of tumour depth would enable further bcc's included for superficial non-invasive treatment modalities such as topical photodynamic therapy.

Condition Intervention
Carcinoma, Basal Cell Procedure: Curretage

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Relation of Basal Cell Carcinoma Tumour Thickness, Histologically Estimated, in Punch Biopsies Performed Before and After Curretage.

Further study details as provided by Norwegian University of Science and Technology:

Primary Outcome Measures:
  • Reduction of tumour thickness 0,5mm or more after curretage [ Time Frame: 1 hour ]

Secondary Outcome Measures:
  • Comparison of tumour thickness in punch biopsies performed on referral, before and after curretage. [ Time Frame: 3 months ]

Enrollment: 36
Study Start Date: April 2002
Study Completion Date: December 2004
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: curettage Procedure: Curretage

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • bcc with tumour depth two mm.or more

Exclusion Criteria:

  • bcc tumours smaller than three mm in mean diameter.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00237107

Sponsors and Collaborators
Norwegian University of Science and Technology
Investigators
Principal Investigator: Eidi Christensen, MD St. Olav University Hospital, Trondheim
  More Information

Publications:
Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00237107     History of Changes
Other Study ID Numbers: EC-003
Study First Received: October 10, 2005
Last Updated: July 18, 2016
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Norwegian University of Science and Technology:
Cytoreduction Surgical Procedures
Curretage
Photochemotherapy

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Basal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Basal Cell

ClinicalTrials.gov processed this record on June 27, 2017